VYD2311 - (LIBERTY)

June 16, 2026: Invivyd, Inc. (NASDAQ: IVVD) announced that enrollment is complete in LIBERTY, a Phase 3 randomized, double-blind study comparing its investigational COVID-19 monoclonal antibody VYD2311 versus an mRNA COVID-19 vaccine in healthy adults, and also evaluating safety and immune response when VYD2311 and an mRNA vaccine are co-administered. Total enrollment is ~210 participants. A primary endpoint assesses side effects and tolerability through Day 6 (7 days total). Invivyd expects to report initial/topline LIBERTY results in Q3 2026, potentially alongside data from its pivotal Phase 3 DECLARATION trial.

DECLARATION (Phase 3; randomized, triple-blind, placebo-controlled) is evaluating VYD2311 efficacy and safety for prevention of symptomatic COVID-19 at three months in a broad population including adults and adolescents with and without risk factors; dosing includes a single dose or monthly intramuscular doses versus placebo, with ~2,400 participants.

LIBERTY and DECLARATION are part of the company’s broader REVOLUTION clinical program intended to support VYD2311 as a potential alternative to vaccination for COVID-19 prevention, subject to approval.